Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in New Jersey: - Trinitas Hospital and Comprehensive Cancer Center - Williamson Street Campus — Elizabeth, New Jersey
- Jersey City Medical Center — Jersey City, New Jersey
- Saint Barnabas Medical Center — Livingston, New Jersey
- Monmouth Medical Center — Long Branch, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in New Jersey: - Cooper Hospital University Medical Center — Camden, New Jersey
- Hackensack University Medical Center — Hackensack, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- Robert Wood Johnson University Hospital Somerset — Somerville, New Jersey
- Community Medical Center — Toms River, New Jersey
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
- Holy Name Hospital — Teaneck, New Jersey
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
- Sidney Kimmel Cancer Center Washington Township — Sewell, New Jersey
Phase 3 Recruiting Academic/Other
This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07200830
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- AtlantiCare Health Park-Cape May Court House — Cape May Court House, New Jersey
- AtlantiCare Surgery Center — Egg Harbor, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in New Jersey: - MSK Basking Ridge — Basking Ridge, New Jersey
- MSK Monmouth — Middletown, New Jersey
- MSK Bergen — Montvale, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRP…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey ( Site 0033) — New Brunswick, New Jersey
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in New Jersey: - Atlantic Health System Morristown Medical Center ( Site 0115) — Morristown, New Jersey
- Rutgers Cancer Institute of New Jersey ( Site 0033) — New Brunswick, New Jersey
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in New Jersey: - East Orange Campus of the VA New Jersey Health Care System, East Orange, NJ — East Orange, New Jersey
Phase 3 Recruiting Academic/Other
In this study the investigators will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the standard boost approach of radiation therapy for participants with intermediate-…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07548164
Sites in New Jersey: - Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering at Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering at Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 3 Recruiting Academic/Other
The purpose of this study is to look whether using local anesthesia during a transperineal prostate biopsy, while put to sleep by IV sedation, helps reduce the number of people who feel significant pain in the recovery room. The researcher…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06986083
Sites in New Jersey: - Memorial Sloan Kettering Cancer Center at Basking Ridge (Consent Only) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Consent Only) — Montvale, New Jersey
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05785741
Sites in New Jersey: - Research site 119 — Florham Park, New Jersey
Phase 2 Recruiting Industry
This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine us…
Sponsor: Monte Rosa Therapeutics, Inc
NCT ID: NCT07745361
Sites in New Jersey: - START New Jersey — East Brunswick, New Jersey
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant pr…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06457919
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
To determine the effects of exercise therapy on molecular, radiologic, and pathologic nimbosus hallmarks versus usual care control in men on Active Surveillance for localized prostate cancer.
Sponsor: City of Hope Medical Center
NCT ID: NCT05751434
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited protocol activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited protocol activities) — Montvale, New Jersey
Phase 2 Recruiting Industry
Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation t…
Sponsor: Candel Therapeutics, Inc.
NCT ID: NCT07332000
Sites in New Jersey: - Summit Health — Saddle Brook, New Jersey
Phase 2 Recruiting Academic/Other
The purpose of this study is to see whether giving a lower (de-escalated) dose of radiation therapy to some parts of the prostate can reduce side effects compared to giving the same (uniform) dose of radiation therapy to the whole prostate.
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07635238
Sites in New Jersey: - Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering at Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering at Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 1, Phase 2 Recruiting Industry
The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expan…
Sponsor: GlaxoSmithKline
NCT ID: NCT06990880
Sites in New Jersey: - GSK Investigational Site — East Brunswick, New Jersey
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether BMS986365 in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects for people w…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT07335796
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
Male adults with a confirmed diagnosis of prostate adenocarcinoma who meet criteria for localized high risk prostate cancer according to the NCCN guidelines and who are eligible for prostatectomy will be invited to participate. Criteria fo…
Sponsor: Hackensack Meridian Health
NCT ID: NCT06798558
Sites in New Jersey: - John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in New Jersey: - Exelixis Clinical Site #88 — East Brunswick, New Jersey
- Exelixis Clinical Site #105 — Hackensack, New Jersey
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…
Sponsor: Pfizer
NCT ID: NCT03460977
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Phase 1 Recruiting Industry
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with adv…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT04729114
Sites in New Jersey: - Garden Sate Urology — Morristown, New Jersey
Phase 1 Recruiting Industry
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
Sponsor: Clasp Therapeutics, Inc.
NCT ID: NCT06778863
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey